EUCTR2020-005860-69-SE招募中1 期
OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety. - ODE
niversity of Gothenburg0 个研究点目标入组 180 人开始时间: 2021年3月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Signed informed consent.
- •2. Age: 25-65 on the day of screening.
- •3. Meeting DSM-5 criteria for major depressive disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI).
- •4. A symptom-free period preceding the current episode within the past two years confirmed at interview.
- •5. Not significantly improved, as judged by both doctor and patient, after having been treated with citalopram, escitalopram, paroxetine, sertraline, fluoxetine, duloxetine, or venlafaxine for at least 6 weeks.
- •6. Displaying a sum score of MADRS =22.
- •7. In women of childbearing potential (WOCBP): negative result of a pregnancy test and a method of contraception with a failure rate of less than 1 %. Contraception must be used during the treatment and follow-up period. Acceptable forms of contraception are:
- •a) Use of combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation
- •- intravaginal
- •- transdermal
- •b) progestogen-only hormonal contraception associated with inhibition of ovulation:
- •- injectable
- •- implantable
- •c) Placement of intrauterine device (IUD) or intrauterine hormone releasing system (IUS)
- •d) Bilateral tubal occlusion or ligation
- •e) Vasectomised partner (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate and provided that male partner is the sole sexual partner of the WOCBP trial participant).
- •f) Sexual abstinence.
- •8. Male patients must agree to use condoms during the study and for 2 weeks after the end of the study/last dose of IMP, unless their partner is using a highly efficient method of contraception, as described above.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 180
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Meeting MINI criteria at interview for suicidality, manic episode, hypomanic episode, bipolar I, bipolar II, bipolar unspecified, bipolar I with psychotic symptoms, panic disorder (current), agoraphobia, social anxiety (social phobia), obsessive compulsive disorder, posttraumatic stress disorder, alcohol dependency, alcohol abuse, substance dependency (non-alcoholic), substance abuse (non-alcoholic), psychotic disorders, mood disorders with psychotic features, anorexia nervosa, bulimia nervosa, anorexia nervosa binge eating / purging type, generalised anxiety disorder, or antisocial personality disorder. Meeting MINI criteria at interview for generalised anxiety disorder, obsessive compulsive disorder or social anxiety (social phobia), unless the present symptoms can predominantly be attributed to a diagnosis of major depressive disorder.
- •2. A history of substance/alcohol abuse within 2 years prior to screening.
- •3. A previous diagnosis of a personality disorder, autism spectrum disorder, attention-deficit/hyperactivity disorder, or intellectual disability.
- •4. Any other previously diagnosed or suspected CNS disorder that according to the investigator renders the patient unsuitable for participation in the trial.
- •5. Any factor that according to the investigator renders it unlikely that the patient will comply with the instructions regarding treatment, visits etc.
- •6. Any somatic illness that according to the investigator renders the patient unsuitable for participation in the trial.
- •7. Any signs or symptoms of somatic illness resulting from assessment of vital signs, physical examination, clinical laboratory tests and 12-lead ECG that according to the investigator renders the patient unsuitable for participation for safety reasons, including a QTc-time on ECG exceeding 450 ms in men and 460 ms in women.
- •8. Any change in dosage of said SSRI/SNRI within 4 weeks prior to screening or at any time during the course of the trial.
- •9. Treatment with any other psychoactive drug than said SSRI/SNRI with the exception of using mirtazapine up to 15 mg for sleep, occasional use of benzodiazepines and benzodiazepine-like anxiolytics or hypnotics and occasional use of antihistaminergic sedatives (without anti-dopaminergic effects) within 4 weeks prior to screening and at any time during the course of the trial.
- •10. Patients who are receiving concomitant therapy with potent cytochrome P450 enzyme inhibitors (e.g., bupropion, fluvoxamin, ketoconazol, itraconazole, telitromycin, clarithromycin, protease inhibitors, quinidine, and terbinafine).
- •11. Ongoing treatment with drugs with a narrow therapeutic window where either lower or higher serum levels are potentially harmful (including but not limited to warfarin along with other anticoagulants, digoxin along with other antiarrythmics, anticonvulsants prescribed for treatment of epilepsy, cyclosporine, immunosuppressants, and lithium).
- •12. Current treatment with any prescribed or OTC drug that according to the investigator renders the subject unsuitable for participation in the trial.
- •13. Previous intake of OSU6162.
- •14. Current participation in another clinical trial.
- •15. Nursing women.
- •16. Substudy only: Relative and/or absolute contraindications to lumbar puncture and functional Magnetic Resonance Imaging (fMRI), as per clinical practice.
研究者
相似试验
招募中
2 期
OSU6162 as add-on in SSRI/SNRI-resistant DepressionDepressive Disorder, Treatment-ResistantDepressive DisorderDepressive EpisodeRecurrent Depressive DisorderRecurrent DepressionDepressionNCT05641623Göteborg University180
已完成
3 期
Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake InhibitorsDepressive DisorderNCT00296517GlaxoSmithKline325
Unknown
4 期
A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward PathwayDiagnosis and Treatment of DepressionNCT03148509Peking University300
尚未招募
4 期
A clinical trial to study the effect of a combination therapy (oral ketamine and escitalopram) and escitalopram alone in elderly patient with depression, when given early in the course of treatment.CTRI/2023/04/051777King George Medical University
进行中（未招募）
1 期
A randomised placebo controlled trial in which mirtazapine, an antidepressant, is added for patients with depression in primary care who have not responded to treatment with first-line antidepressants.Treatment resistant depressionMedDRA version: 16.0Level: LLTClassification code 10045543Term: Unipolar depressionSystem Organ Class: 100000004873EUCTR2012-000090-23-GBniversity of Bristol470